We are live on !
Find out more
Pharmstandard International Portfolio holdings
AUM
$29M
Turnover
14.29%
1-Year Est. Return
13.35%
This Fund
S&P 500
This Quarter Est. Return
-1.24%
1 Year Est. Return
+13.35%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$29M
AUM Growth
+$4.11M
(+16%)
Cap. Flow
+$6.47M
Cap. Flow % of AUM
Cap. Flow %
22.27%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
1
Closed
–
Avg Time Held
Equity + Options
1.3
years
Top 10 Avg Time Held
Equity + Options
1.3
years
Top 20 Avg Time Held
Equity + Options
1.3
years
Avg Time Held Equity only
1.3
years
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NTGN
Neon Therapeutics, Inc. Common Stock
NTGN
|
+$6.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALNA
Allena Pharmaceuticals
ALNA
|
+$56.1K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.91% |
| 2 | Miscellaneous | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ALNA
1
DELISTED
Allena Pharmaceuticals
ALNA
| $9.38M | 32.28% |
873,031
-5,100
| -0.6% | -$56.1K |
2017 Q4
3 quarters
|
|
2
Protagonist Therapeutics
PTGX
$9.03B
| $7.72M | 26.59% |
750,632
| – | – |
2016 Q4
7 quarters
|
|
|
NTGN
3
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $5.03M | 17.31% |
+588,611
| New | +$6.52M |
2018 Q3
0 quarters
|
|
|
JNCE
4
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $3.67M | 12.65% |
565,063
| – | – |
2017 Q1
6 quarters
|
|
5
Protara Therapeutics
TARA
$144M
| $3.14M | 10.79% |
40,195
| – | – |
2016 Q4
7 quarters
|
|
|
ARGS
6
DELISTED
Argos Therapeutics, Inc.
ARGS
| $83K | 0.29% |
826,153
| – | – |
2016 Q4
7 quarters
|
|
|
ARGS
7
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
| $26K | 0.09% |
256,030
| – | – |
2016 Q4
7 quarters
|
|
Similar funds
IP
FHAM
Pharmstandard International's Q3 2018 Portfolio in Review
As of Q3 2018, Pharmstandard International held 7 positions worth $29M, up 16% from $24.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Pharmstandard International deployed $6.47M of net new capital in Q3 2018, opening 1 new position. Its largest new stake was Neon Therapeutics, Inc. Common Stock: 588,611 shares worth $5.03M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Allena Pharmaceuticals, an estimated $56.1K trimmed.
- Pharmstandard International's largest Q3 2018 buy was Neon Therapeutics, Inc. Common Stock: 588,611 shares worth $5.03M.
- Pharmstandard International's biggest Q3 2018 reduction was Allena Pharmaceuticals, cutting an estimated $56.1K.
- Pharmstandard International's ten largest holdings make up 100% of its $29M portfolio in Q3 2018.
- Pharmstandard International opened 1 new position and closed 0 in Q3 2018.
- Pharmstandard International's portfolio value rose 16% quarter-over-quarter to $29M.
Based on Pharmstandard International's 13F filing for Q3 2018, filed 15 Nov 2018.